

'COPD Salford Lung Study'; updates at Asthma & COPD 2017

SMi Group will return to London with their 13th annual Asthma and COPD conference taking place on the 29-30 March 2017

LONDON, UNITED KINGDOM, November 24, 2016 /EINPresswire.com/ -- The 2017 line-up includes: MHRA, GlaxoSmithKline, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Novartis, Teva UK, AstraZeneca, MedImmune, Mylan, Actavis and many more who will explore leading strategies to novel treatments and solutions to these respiratory diseases.

David Leather, Global Medical Affairs Leader at GSK, will present an unmissable [case study](#) on the Salford Lung Study, an innovative and novel approach to drug trials. This is a pioneering first-of-its-kind study, giving unique data on the effects of the drug Relvar/Ellipta in COPD and Asthma patients throughout the town of Salford.



"GSK announce positive results from the COPD Salford Lung Study published in the NEJM...The results show a superior reduction in exacerbations for COPD patients on Relvar / Ellipta." (*Source)

“

Following the release of positive results in September 2016, this is a unique opportunity to hear the latest updates of the study first hand from GSK

SMi Group

Following the release of positive results in September 2016, this is a unique opportunity to hear the latest updates of the study first hand from GSK.

Dr Leather will provide an overview including aims and background of the project as well as speak on the benefits of real time data collection and if this has the potential to set trends for future studies and as a potential alternative to randomised controlled trials.

Other topics to be discussed include: regulatory updates, new inhalation devices and biomarkers and biologics. To view the two day programme visit the [event website](#).

Two CPD certified [pre-conference workshops](#) will be hosted alongside the conference by Cambridge Consultants and Janssen.

There is currently an early bird offer available; book by 30th of November to save £400 off the conference price. Register at www.asthma-copd.co.uk/EIN

For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-

online.co.uk

For delegate enquiries: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.uk

For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk

13th annual Asthma & COPD

29-30 March 2017

London, UK

www.asthma-copd.co.uk/EIN

Contact e-mail: zgale@smi-online.co.uk

Contact tel: +44 (0) 207 827 6166

#asthmacopdsmi

*(Source) <http://bit.ly/2fH6rby>

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Zoe Gale
SMi Group
02078276054
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.